Pricing

Five things for pharma marketers to know: Friday, February 12, 2016

Five things for pharma marketers to know: Friday, February 12, 2016

By

Aegerion slashes workforce; GSK president says downward pressure on drug prices is here to stay; Novartis acquires European rights to Remicade biosimilar

House Oversight committee upbraids Turing, Valeant execs

House Oversight committee upbraids Turing, Valeant execs

By

A House lawmaker called pricing strategies used by Turing and Valeant "repulsive."

Five things for pharma marketers to know: Thursday, February 4, 2016

Five things for pharma marketers to know: Thursday, February 4, 2016

By

Valeant to push for changes to financial-assistance rules; House to hold hearing on drug-pricing practices; FDA committee says Lundbeck can add information to leaflet

A Competitive Market is Good for US Patients

A Competitive Market is Good for US Patients

We look forward to collaborating with stakeholders across the healthcare system—including PBMs—to extend success to disease states beyond hepatitis C, writes PhRMA CEO Stephen Ubl.

4 Ways to Create a Sustainable Pricing Model

4 Ways to Create a Sustainable Pricing Model

The formula's pretty simple: Be sure you can defend your drug's value proposition, without blushing, says BioPharma Alliance's Mike Luby.

Medicines360 CEO battles for IUD access

Medicines360 CEO battles for IUD access

By

Prior to Medicines360's arrival on the scene, there were only three IUDs on the market. The lack of competition drove prices sky-high.

Five things for pharma marketers to know: Wednesday, January 20, 2016

Five things for pharma marketers to know: Wednesday, January 20, 2016

By

Part of drugmakers' sales growth stems from price increases; AbbVie's Venetoclax gets second Breakthrough designation; two states in India stop Avastin sales

Five things for pharma marketers to know: Tuesday, January 19, 2016

Five things for pharma marketers to know: Tuesday, January 19, 2016

By

Government pressure can influence drug-pricing decisions; Samsung's biosimilar version of Enbrel is approved in Europe; J&J to cut jobs in medical-devices business

Five things for pharma marketers to know: Thursday, January 14, 2016

Five things for pharma marketers to know: Thursday, January 14, 2016

By

Valeant is "uncertain" when CEO will return; Bayer hires Razorfish and iCrossing for digital; more drugmakers that sell hemophilia drugs are hiring patients

The year's top pharma marketing controversies

The year's top pharma marketing controversies

By

Drug pricing is easily the biggest controversy but pharma faced other issues, too, like the AMA's call to ban DTC advertising.

DCI Group aids Turing amid drug price, Shkreli controversies

DCI Group aids Turing amid drug price, Shkreli controversies

By

The firm began working with the pharma company before outrage over its drug pricing but has more recently supported the client after former CEO Martin Shkreli was arrested.

New cardiovascular drugs raise concerns about pricing, efficacy

New cardiovascular drugs raise concerns about pricing, efficacy

By

With the huge advances in treatment comes a raft of concerns, among them daunting pricing pressures.

Five things for pharma marketers to know: Monday, December 21, 2015

Five things for pharma marketers to know: Monday, December 21, 2015

By

Shkreli resigns from Turing; Keytruda approved as first-line melanoma treatment; drugmakers seek to fend off California pricing ballot initiative

Five things for pharma marketers to know: Wednesday, December 16, 2015

Five things for pharma marketers to know: Wednesday, December 16, 2015

By

Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials

Five things for pharma marketers to know: Monday, December 14, 2015

Five things for pharma marketers to know: Monday, December 14, 2015

By

Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug

Five things for pharma marketers to know: Friday, December 11, 2015

Five things for pharma marketers to know: Friday, December 11, 2015

By

UnitedHealth gives Praluent preferred status on its formularies; Stat News examines the first DTC drug ad; Britain to cover Entresto

Five things for pharma marketers to know: Wednesday, December 9, 2015

Five things for pharma marketers to know: Wednesday, December 9, 2015

By

Pfizer reveals Ibrance pricing strategy; AMA call for DTC ban may resonate due to pricing debate; Baxalta's Vonvendi receives FDA approval

Five things for pharma marketers to know: Monday, December 7, 2015

Five things for pharma marketers to know: Monday, December 7, 2015

By

Gleevec generic is approved; FDA issues warning on diabetes drugs; Senate will hold hearing on drug pricing

Five things for pharma marketers to know: Friday, December 4, 2015

Five things for pharma marketers to know: Friday, December 4, 2015

By

Pharma M&A expected to continue in 2016; Mylan receives government subpoena about marketing and pricing for doxycycline; KaloBios acquired rights to experimental drug to treat Chagas disease

Why drug companies need to go from reactive to proactive on pricing

Why drug companies need to go from reactive to proactive on pricing

By

Drug pricing has been in the spotlight since early this fall, thanks to Turing Pharmaceuticals and Martin Shkreli. One thing pharma companies can do is to communicate more proactively.

Five things for pharma marketers to know: Tuesday, December 1, 2015

Five things for pharma marketers to know: Tuesday, December 1, 2015

By

Gilead criticized over Sovaldi pricing strategy; analysis finds branded drugs cost more in the US; support is growing for Medicare negotiation of drug prices

Drugmakers explore response to pricing debate

Drugmakers explore response to pricing debate

By

Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.

Valeant woes continue, with lawsuit and new Philidor allegations

Valeant woes continue, with lawsuit and new Philidor allegations

By

The embroiled drugmaker now faces allegations that it violated securities law and that its staff was embedded in Philidor's day-to-day operations.

Five things for pharma marketers to know: Friday, November 6, 2015

Five things for pharma marketers to know: Friday, November 6, 2015

By

Obama administration tells states they cannot restrict hep-C drugs; AstraZeneca says it will acquire ZS Pharma: Allergan CEO says drug discovery is too risky

Five things for pharma marketers to know: Thursday, November 5, 2015

Five things for pharma marketers to know: Thursday, November 5, 2015

By

Pfizer increases the financial assistance it gives to patients; Senate committee opens investigation into drug pricing; OptumRx reportedly stopped business with Philidor a year ago

Pharma CEOs defend R&D model to investors

Pharma CEOs defend R&D model to investors

By

Executives at Eli Lilly, Merck and Biogen used the most recent earnings season to promote innovation and defend drug pricing.

Drugmakers spend too much on marketing: Kaiser poll

Drugmakers spend too much on marketing: Kaiser poll

By

The public said drugmakers spend too much money on marketing to doctors and patients

Editor's Desk: Escaping the Shkreli Cycle

Editor's Desk: Escaping the Shkreli Cycle

By

Three suggestions for defusing the highly charged pricing atmosphere

Five things for pharma marketers to know: Monday, October 19, 2015

Five things for pharma marketers to know: Monday, October 19, 2015

By

The FDA approves Pradaxa antidote; Valeant CEO says he expects a new pricing environment in 2016; FDA denies Shire dry-eye drug

Five things for pharma marketers to know: Thursday, October 15, 2015

Five things for pharma marketers to know: Thursday, October 15, 2015

By

Valeant receives subpoenas over drug pricing; BMS signs new immuno-oncology deal with Five Prime Therapeutics; Pfizer CEO says insurance coverage to blame in price debate

Email Newsletters